Characterization of the Interaction between the Herpes Simplex Virus Type I Fc Receptor and Immunoglobulin G by Chapman, Tara L. et al.
Characterization of the Interaction between the Herpes Simplex
Virus Type I Fc Receptor and Immunoglobulin G*
(Received for publication, October 27, 1998)
Tara L. Chapman‡, Il You§, Ian M. Joseph§, Pamela J. Bjorkman‡¶, Sherie L. Morrisoni, and
Malini Raghavan§**
From the ‡Division of Biology 156-29 and the ¶Howard Hughes Medical Institute, California Institute of Technology,
Pasadena, California 91125, the §Department of Microbiology and Immunology, University of Michigan Medical School
Ann Arbor, Michigan 48109, and the iDepartment of Microbiology, Immunology, and Molecular Genetics, UCLA,
Los Angeles, California 90095
Herpes simplex virus type I (HSV-1) virions and HSV-
1-infected cells bind to human immunoglobulin G (hIgG)
via its Fc region. A complex of two surface glycoproteins
encoded by HSV-1, gE and gI, is responsible for Fc bind-
ing. We have co-expressed soluble truncated forms of gE
and gI in Chinese hamster ovary cells. Soluble gE-gI
complexes can be purified from transfected cell super-
natants using a purification scheme that is based upon
the Fc receptor function of gE-gI. Using gel filtration
and analytical ultracentrifugation, we determined that
soluble gE-gI is a heterodimer composed of one molecule
of gE and one molecule of gI and that gE-gI het-
erodimers bind hIgG with a 1:1 stoichiometry. Biosen-
sor-based studies of the binding of wild type or mutant
IgG proteins to soluble gE-gI indicate that histidine 435
at the CH2-CH3 domain interface of IgG is a critical res-
idue for IgG binding to gE-gI. We observe many similar-
ities between the characteristics of IgG binding by gE-gI
and by rheumatoid factors and bacterial Fc receptors
such as Staphylococcus aureus protein A. These obser-
vations support a model for the origin of some rheuma-
toid factors, in which they represent anti-idiotypic an-
tibodies directed against antibodies to bacterial and
viral Fc receptors.
The expression of viral proteins that counter immune re-
sponses of the host is well documented. Viral factors have been
identified that can potentially inhibit or modify the antiviral
effects of antibodies, complement proteins, cytokines, and cy-
totoxic T cells (1). Characterization of viral proteins that inter-
act with specific components of the immune system is likely to
provide insights into immune mechanisms involved in host-
virus interactions and into the molecular basis of viral persist-
ence in the presence of a functional immune system. Herpesvi-
ruses, in particular, have evolved multiple mechanisms for
interfering with humoral as well as cell-mediated immune re-
sponses (reviewed in Refs. 2 and 3). The present studies focus
upon the herpes simplex virus type I-encoded Fc receptor
(FcR),1 a protein complex that has been suggested to interfere
with antibody-mediated viral clearance (4). HSV-1 virions, as
well as cells infected with HSV-1, bind to immunoglobulins of
the IgG subclass via the Fc region (5). The glycoprotein gE of
HSV-1 was identified as the IgG-binding polypeptide of HSV-1
(6, 7). It was subsequently shown that gE associates with a
second viral glycoprotein, gI (8, 9), and that cells transfected
with genes encoding both gE and gI have enhanced IgG binding
activity compared with cells transfected with gE alone (10–12).
Both gE and gI are type I transmembrane proteins, with an
N-terminal extracellular portion, a single transmembrane do-
main, and a C-terminal cytoplasmic domain. Homologous gly-
coproteins encoded by other a-herpesviruses, including pseu-
dorabies virus (PRV) (13) and varicella zoster virus (14), have
been shown to possess species-specific FcR activity.
HSV-1-infected cells acquire low levels of FcR activity imme-
diately upon exposure to virus (in the absence of viral gene
expression), presumably by the transfer of virion gE-gI to the
cell surface during viral entry (7). The HSV FcR may thus be
particularly significant for protection of virally infected cells
from early immune destruction (2). Recent in vivo studies dem-
onstrated that passively transferred anti-HSV IgG greatly re-
duced viral titers and disease severity in mice infected with a
mutant HSV-1 that lacked FcR activity. By contrast, anti-HSV
IgG was ineffective in reducing viral titers and disease severity
in mice infected with wild type virus with intact FcR activity
(15). These observations indicate that the HSV-1 FcR activity
facilitates evasion of antibody-mediated viral clearance in vivo.
Several means of evading antibody-mediated immune re-
sponses could arise from the Fc binding function of gE-gI (16–
18). Binding of nonimmune IgG by gE-gI present on HSV-1
virions can inhibit virus neutralization by anti-viral antibodies
(19). Engagement of the Fc portion of anti-HSV antibodies can
protect virally infected cells from antibody-dependent cell-me-
diated cytotoxicity (ADCC) (20) as well as complement-medi-
ated lysis (21). Inhibition of ADCC has been suggested to occur
by a phenomenon called antibody bipolar bridging (21), a mech-
anism whereby antibodies bound via their Fab ends to HSV-1
glycoproteins on surface membranes of infected cells would
simultaneously interact with the viral Fc receptors of the same
infected cell. By engaging the Fc domain, the HSV-1 FcR could
interfere with recognition by FcgRs on immune effector cells.
Antibody bipolar bridging has also been suggested to facilitate
antiviral antibody-induced patching, capping, and extrusion of
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viral glycoproteins from the surface of cells infected with PRV
(13). Antibody-induced shedding of viral glycoproteins may rep-
resent a strategy for rendering virally infected cells refractory
to antiviral antibodies and for inhibiting the presentation of
viral antigens via class II major histocompatibility complex
molecules.
A second function attributed to gE-gI is that of facilitating
cell-to-cell spread of virus. Recent studies suggest that gE and
gI are required for transneuronal transport of PRV from the
retina to the visual centers of rats (22), for cell-to-cell spread of
PRV, and for full virulence of PRV (23). Furthermore, studies
with mutant HSV-1 virions indicate that gE and gI of HSV-1
facilitate cell-to-cell spread of virus in vivo and viral spread
across junctions of cultured cells (24–26). It has been proposed
that the cell-to-cell spread-promoting functions of gE-gI are
unrelated to the Fc binding activity and that the HSV-1-
encoded gE-gI glycoproteins and the analogous proteins of
other a-herpesviruses may interact with other ligands, ena-
bling viral transport across cells (24, 25). Such ligands remain
to be identified.
To better understand the mechanisms by which IgG binding
by gE-gI facilitates immune evasion, we initiated a molecular
characterization of IgG binding by gE-gI. We expressed soluble
forms of gE and gI and showed that the glycoproteins assemble
into a stable heterodimer. The soluble receptor heterodimer
binds to human IgG (hIgG) with relatively high affinity and can
be purified to homogeneity using an hIgG-based affinity ma-
trix. We determined a 1:1 binding stoichiometry for the gE-
gIzIgG complex, and also determined that a histidine residue at
the CH2-CH3 domain interface is a critical determinant of IgG
binding specificity. The implications of the gE-gI binding site
on IgG and the gE-gIzIgG complex stoichiometry are discussed.
EXPERIMENTAL PROCEDURES
Construction and Expression of Soluble gE, gI, and gE-gI—Molecular
cloning manipulations were performed by standard protocols (27). PCR
was used to insert a 59 XhoI site, a 39 NotI site, and a stop codon after
the codon corresponding to amino acid 399 of the gE gene and amino
acid 246 of the gI gene (the HindIII fragment containing the gE gene
and the BamHI fragment containing the gI gene of HSV strain KOS
was kindly provided by H. Ghiasi, Cedar Sinai Medical Center). Our
numbering scheme starts with the first residue of the mature protein,
which is designated residue 1, and all other residues are numbered
sequentially (see “N-Terminal Sequencing and Mass Spectrometric
Analysis of Purified gE-gI”). The gE PCR product was cloned into pCRII
(Invitrogen), and the gI PCR product was cloned into pBSIISK1 (Strat-
agene). Both sequences were verified. The modified gE and gI genes
were excised using XhoI and NotI enzymes and individually subcloned
into the unique XhoI and NotI sites of separate PBJ5-GS expression
vectors (28). PBJ5-GS carries the glutamine synthetase gene as a se-
lectable marker and as a means of gene amplification in the presence of
the drug methionine sulfoximine, a system developed by Celltech (29).
Expression vectors carrying gE, gI, or both gE and gI were transfected
into CHO cells using a Lipofectin procedure (Life Technologies, Inc.).
Cells resistant to 100 mM methionine sulfoximine were selected accord-
ing to the protocol established by Celltech, modification of which has
been previously described (28). Transfected CHO cells were maintained
in glutamine-free a-minimal essential medium (Irvine Scientific) sup-
plemented with 5% dialyzed fetal bovine serum (Life Technologies), 100
mM methionine sulfoximine (Sigma), penicillin (100 units/ml), and
streptomycin (100 mg/ml). Cells secreting gE, gI, or both gE and gI were
identified by immunoprecipitation of supernatants of cells metaboli-
cally labeled with [35S]methionine and [35S]cysteine (see below) by
using either an antibody against gE (1108 (Goodwin Institute) or Fd172
(30) (kindly provided by Subbu Chatterjee) or an antibody against gI
(Fd69 (31), kindly provided by Subbu Chatterjee) Clones were consid-
ered positive if immunoprecipitation yielded a protein of approximately
56 kDa corresponding to gE or a protein of approximately 43.5 kDa
corresponding to gI. The identity of each protein was verified using
N-terminal sequencing (see below).
35S Metabolic Labeling—gE-, gI-, and gE-gI-transfected CHO cell
lines derived from colonies were expanded into 12-well trays, grown to
confluence, and incubated for 5 h in 1.0 ml of methionine- and cysteine-
free medium (Life Technologies) plus 1% dialyzed fetal bovine serum
including 5 mCi of a [35S]methionine and [35S]cysteine (ICN) mixture.
Supernatants were clarified by a 5-min spin in a microcentrifuge, and
either anti-gE or anti-gI antibodies were added. Immunoprecipitations
were carried out by standard methods (32) with protein G-bearing
Sepharose beads (Amersham Pharmacia Biotech). Samples were boiled
in SDS-polyacrylamide gel electrophoresis (SDS-PAGE) running buffer
and loaded onto 15% polyacrylamide gels, which were fixed, dried, and
exposed to a PhosphorImager screen (Molecular Dynamics, Inc., Sunny-
vale, CA). The image was then developed with a Molecular Dynamics
425E PhosphorImager scanner.
Co-Expression of Full-length gE and gI—PCR was used to insert a 59
XhoI site and a 39 NotI site into the genes encoding gE and gI. The PCR
products were sequenced and subsequently individually subcloned into
the unique XhoI and NotI sites of separate PBJ5-GS expression vectors.
The two constructs were co-transfected into CHO cells, and cells resist-
ant to 100 mM methionine sulfoximine were selected. Cells expressing
both gE and gI were sorted using fluorescence activated cell sorting
(FACS) analysis with FITC-labeled hIgG. Individual clones from the
sort were amplified and subsequently shown to express both gE and gI
by FACS analysis with 1108 or Fd69 as the primary antibodies and a
goat anti-mouse IgG as the secondary antibody. Sorting and analysis
were performed on a Coulter Epics Elite flow cytometer.
Purification of Soluble gE-gI Heterodimers—gE-gI-secreting CHO
cell lines were grown to confluence in 50 10-cm plates and introduced
into a hollow bioreactor device (Cell Pharm I; Unisyn Fibertec, San
Diego, CA) in serum-free medium, and supernatants were collected
daily. Soluble gE-gI heterodimers were purified from supernatants on
either a human Fc or hIgG affinity column. The human Fc column was
prepared by coupling 20 mg of human Fc (Jackson ImmunoResearch
Laboratories, Inc.) to cyanogen bromide-treated Sepharose 4B (Amer-
sham Pharmacia Biotech) at approximately 10 mg of protein/ml of resin
according to the protocol of the manufacturer. The hIgG column was
prepared similarly using 70 mg of hIgG (Sigma). Supernatants were
passed over the affinity column, which was then washed with 50 column
volumes of a solution consisting of 50 mM Tris (pH 7.4), 0.1% NaN3, and
1 mM EDTA. Bound gE-gI was eluted from the column with 50 mM
diethylamine (pH 11.5) into tubes containing 1.0 M Tris (pH 7.4). gE-gI
heterodimers were further purified using a Superdex 200 HR 10/30 fast
protein liquid chromatography (FPLC) filtration column. Approxi-
mately 10 mg of gE-gI heterodimers were recovered per liter of trans-
fected cell supernatants.
N-terminal Sequencing and Mass Spectrometric Analysis of Purified
gE-gI—N-terminal sequencing was performed on 2.5 mg of purified,
soluble gE-gI in a phosphate buffer dried onto a polyvinylidene difluo-
ride membrane and inserted into an Applied Biosystems model 476A
sequencer reaction cartridge. Two sequences were isolated from the
gE-gI sample: the sequence GTPKTSWRR, corresponding to the first 9
amino acids of mature gE (33), and the sequence LVVRGPTVS, corre-
sponding to the first 9 amino acids of mature gI (33). The molecular
masses of gE and that of gI were determined by matrix-assisted, laser
desorption, time-of-flight mass spectrometry with a PerSeptive biosys-
tems (Farmington, MA) ELITE mass spectrometer.
CD Analyses—An AVIV 62A DS spectropolarimeter equipped with a
thermoelectric cell holder was used for CD measurements. Wavelength
scans and thermal denaturation curves were obtained from samples
containing 10 mM protein in 5 mM phosphate at pH 7 by using a 0.1-mm
path length cell for wavelength scans and a 1-mm path length cell for
thermal denaturation measurements. The heat-induced unfolding of
gE-gI was monitored by recording the CD signal at 223 nm, while the
sample temperature was raised from 25 to 80 °C at a rate of approxi-
mately 0.7 °C/min. The transition midpoint (Tm) for unfolding was
determined by taking the maximum of a plot of du/dT versus T (where
u is ellipticity) after averaging the data with a moving window of 5
points.
Gel Filtration Analyses of gE-gIzhIgG Stoichiometry—Protein concen-
trations were determined spectrophotometrically at 280 nm using the
following extinction coefficients: gE-gI, 88816 M21 cm21; hIgG, 202,500
M21 cm21. The extinction coefficient for the gE-gI heterodimer was
calculated from the amino acid sequences as described (34), and the
extinction coefficient for hIgG is known (32). A280 measurements for a
fixed amount of each protein were then compared in 6 M guanidine HCl
and aqueous solutions, and the extinction coefficients were adjusted as
necessary. For determining the gE-gIzhIgG stoichiometry, various mo-
lar ratios from 1:3 (300 pmol of gE-gI:900 pmol of hIgG) to 3:1 (900 pmol
of gE-gI:300 pmol of hIgG) of gE-gI and hIgG were incubated for 30 min
at room temperature in 20 mM Tris, pH 7.4, 150 mM NaCl, 0.05% NaN3
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in a total volume of 100 ml. Samples were injected onto a Superose 6B
FPLC column (Amersham Pharmacia Biotech) and eluted with the
same buffer at 0.5 ml/min. The composition of each fraction was ana-
lyzed by SDS-PAGE (data not shown).
Equilibrium Analytical Ultracentrifugation—Sedimentation equilib-
rium was performed with a Beckman Optima XL-A analytical ultracen-
trifuge, using data analysis software provided by the manufacturer.
Experiments were performed using 0.6 mg/ml gE-gI at both 4 and 20 °C
at a rotor speed of 10,000 rpm, with equilibrium times of at least 36 h.
Molecular masses were determined by nonlinear least square fit of the
equilibrium gradient, absorbance versus radius (Fig. 3), using the model
of single ideal species, and a partial specific volume, 0.69, calculated
from the amino acid composition and the carbohydrate content (35).
Equilibrium Column Chromatography—The equilibrium column
chromatography method of Hummel and Dreyer (36) was used to ob-
serve the interaction between gE-gI and hIgG. A Superdex 200 PC
3.2/30 gel filtration column of 2.4 ml was connected to an Amersham
Pharmacia Biotech m Precision pump system. Absorbance of the eluant
was monitored at 280 nm with an Amersham Pharmacia Biotech m
Peak monitor. The column was equilibrated with five different concen-
trations of purified hIgG (Sigma): 250 nM, 500 nM, 1 mM, 2.5 mM, and 5
mM each in 20 mM Tris, pH 7.4, 150 mM NaCl. At each concentration,
four 20-ml injections in the appropriate column equilibration buffer
(including the relevant concentration of hIgG) were performed. These
four injections included gE-gI at a concentration equal to that of the IgG
in the column buffer plus no additional hIgG or hIgG at a concentration
equal to 1, 2, or 3 times that of the IgG concentration contained in the
column buffer. Binding experiments were done at 20 °C with a flow rate
of 100 ml/min.
Biosensor Studies—Biosensor studies were performed on a Biacore
2000 instrument. Purified gE-gI was diluted in 10 mM acetate buffer,
pH 4.1, for amine-based coupling to a Biacore chip. Immobilization was
accomplished by initial activation of the sensor chip with 0.2 M N-ethyl-
N9-(dimethylaminopropyl)-carbodiimide and 0.05 M N-hydroxysuccin-
imide. The N-hydroxysuccinimide-ester was then reacted with gE-gI
using the manual injection mode to allow for better control of immobi-
lization levels. Typically, an immobilization level of 200–300 response
units was used for kinetic analyses described in Table I. The remaining
unreacted ester groups were inactivated by 1 M ethanolamine (pH 8.5).
Different concentrations of the chimeric IgG molecules were injected
over the immobilized gE-gI surface, as well as a control protein surface
(murine IgG). A citrate buffer, pH 3.5, was used for regeneration of the
surface between sequential injections. Sensorgrams obtained for IgG
binding to the control surface were subtracted from those obtained for
IgG binding to the gE-gI surface. The BIAevaluation version 3.0 soft-
ware package was used for kinetic analysis. Kinetic constants were
derived by simultaneous fitting to the association and dissociation
phases of the subtracted sensorgrams and global fitting to all curves in
a working set (Fig. 5). A working set consisted of injections of four or five
different concentrations of a hIgG construct over a surface containing
immobilized gE-gI. S.D. values are reported from experiments per-
formed in duplicate or triplicate on different sensor chips (Table I). In
all cases, a 1:1 binding model was used for curve fitting.
The expression of chimeric hIgG molecules was described previously
(37, 38). These molecules are composed of a murine anti-dansyl VH
domain fused to the constant domains (CH1 through CH3) of hIgG4. An
expression vector containing cDNA encoding the hybrid chain was
co-transfected into a non-Ig-producing mouse myeloma line along with
an expression vector containing cDNA encoding a chimeric K light
chain (composed of a murine anti-dansyl VK region fused to the human
CK region). Site-directed mutations were introduced into the chimeric
heavy chain gene to make the hIgG4H435R mutant and the
hIgG3R435H mutant. The hIgG3-hIgG4 chimeras were generated by
exon shuffling as described previously (38).
Determination of KD Values by Cell Binding Assays—Chimeric hIgG4
was iodinated to a specific activity of 16.1 mCi/mg using the chloram-
ine-T method. CHO cell lines expressing full-length gE and gI were
grown to confluence in tissue culture plates. Cells were detached by
incubation with phosphate-buffered saline (pH 7.5), 5 mM EDTA for
20–30 min and collected in binding buffer at pH 7.0 (Hanks’ balanced
salt solution, 10 mM HEPES, 0.25% bovine serum albumin). The cells
were pelleted, washed once with binding buffer (pH 7.0), and resus-
pended in binding buffer (pH 7.0). Cells (1 3 106) were mixed in
duplicate or triplicate assays with labeled hIgG4, different concentra-
tions of unlabeled hIgG4, and binding buffer (pH 7.0) to a total volume
of 0.5 ml. The samples were incubated for 2 h at room temperature.
After completion of the incubations, cells were pelleted for 5 min at
14,000 rpm in an Eppendorf microcentrifuge, the supernatants were
aspirated, and 1.0 ml of cold binding buffer was added. After removal of
the supernatants by aspiration, the tubes were placed in vials, and the
levels of radioactivity were determined using a Beckman Gamma 5500
counter. Nonspecific binding was determined by a similar treatment of
wild type CHO cells. The binding data were analyzed using Scatchard
plots. Assays were performed in triplicate, and the average of the two
most similar readings was used to compute the concentration of bound
IgG.
RESULTS
Co-Expression of Truncated gE and gI Results in Assembly of
a Stable Heterodimer—We constructed soluble versions of both
gE and gI by truncating each of the genes prior to their pre-
dicted transmembrane regions (following the codons for amino
acid 399 of mature gE and amino acid 246 of mature gI). The
modified genes were co-transfected into CHO cells. Transfected
cells were screened by immunoprecipitating supernatants from
metabolically labeled cells with antibodies against either gE or
gI (Fig. 1A). SDS-PAGE analysis of immunoprecipitated pro-
tein from gE-gI positive clones revealed two bands with appar-
ent molecular masses of 56 and 43.5 kDa using either the
anti-gE or anti-gI antibody. The calculated molecular mass of
truncated gE is 42 kDa, and that of gI is 26 kDa; however, both
proteins are glycosylated (two potential N-linked glycosylation
sites in the sequence of gE and three potential sites in the
sequence of gI) and would be expected to migrate with a higher
apparent molecular mass.
HSV-1-infected cells have previously been shown to encode
proteins that bind hIgG but not rodent IgG (39). To investigate
the binding characteristics of soluble gE, gI, and the gE-gI
FIG. 1. Soluble gE and gI assemble into a stable complex. Cells
producing gE, gI, or both gE and gI or nontransfected CHO cells were
labeled with [35S]methionine/cysteine, and cell supernatants were an-
alyzed. A, SDS-PAGE (10%) analysis of protein isolated from superna-
tants of 35S-labeled cells producing gE, gI, or gE-gI using antibodies
against either gE (lanes 1 and 2) or gI (lanes 3 and 4). B, SDS-PAGE
(10%) analysis of gE, gI, and gE-gI binding to either Sepharose-immo-
bilized rat IgG (lanes 1–4) or hIgG (lanes 5–8).
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heterodimer, metabolically labeled supernatants from gE-, gI-,
or gE-gI-secreting cells were incubated with Sepharose-immo-
bilized hIgG or rat IgG. SDS-PAGE analysis revealed that
while none of the proteins bind rat IgG, the gE-gI complex
efficiently bound to the hIgG matrix. gE alone bound only
weakly to the human IgG matrix, while gI alone showed no
specific interaction (Fig. 1B).
A purification scheme based upon the FcR activity of gE-gI
was used to isolate soluble gE-gI heterodimers for biochemical
studies. Supernatants from cells expressing gE-gI were passed
over an hIgG affinity column, eluted at high pH, and then
further fractionated by size exclusion chromatography using a
Superose 6B gel filtration column. A single homogenous peak
corresponding to a gE-gI complex was obtained, demonstrating
that any free gE or gI present in the supernatants does not
efficiently associate with the hIgG matrix. By contrast, gE is
not purified when supernatants from cells expressing only gE
are passed over the hIgG column.
Soluble gE-gI migrates on the gel filtration column slower
than predicted by the molecular mass of a 1:1 heterodimer (100
kDa). Indeed, the retention time for gE-gI is greater than that
for IgG (165 kDa) (Fig. 2C). The increased retention might arise
because gE-gI is not a 1:1 heterodimer or because of anomalous
migration of a 1:1 heterodimer with an elongated or otherwise
nonspherical shape. In order to determine the stoichiometry of
soluble gE-gI, we analyzed the protein by N-terminal sequenc-
ing and equilibrium analytical ultracentrifugation. N-terminal
sequencing of purified gE-gI confirmed the presence of the
correctly processed forms of both proteins in approximately
stoichiometric amounts (data not shown). The molecular mass
of soluble gE-gI determined by equilibrium analytical ultracen-
trifugation is 83.4 kDa (Fig. 3), in close agreement with the
predicted molecular mass of a 1:1 gE-gI heterodimer calculated
using molecular masses of each monomer determined by mass
spectrometry (gE, 48.4 kDa; gI, 33.5 kDa). To investigate the
stability of soluble gE-gI, we used a circular dichroism-based
thermal unfolding assay, from which we determined that the
heterodimer denatures cooperatively with a Tm of 66 °C (data
not shown).
Taken together, these results indicate that gE-gI is a stable
heterodimer with 1:1 stoichiometry and that the heterodimer,
but neither free gE nor free gI, binds to monomeric hIgG with
high affinity. Thus, the observed interaction of free gE with IgG
reported here (Fig. 1B, lane 5) as well as previously (10) must
be low affinity or specific for aggregated IgG (11).
The Stoichiometry of the gE-gIzIgG Complex Is 1:1—The stoi-
chiometry of the gE-gIzhIgG complex was determined to be 1:1
using a non-equilibrium-based gel filtration assay and con-
firmed using an equilibrium column chromatography method
(36). As shown in Fig. 2, gE-gI, IgG, and the gE-gIzhIgG com-
plex each elute as single peaks from a Superose 6B column and
can be distinguished from one another on the basis of their
retention times. To determine the stoichiometry of the gE-
gIzIgG complex, various molar ratios of gE-gI to IgG were
pre-equilibrated and then passed over the Superose 6B column.
When gE-gI and IgG were present at equimolar ratios, a single
peak corresponding to the gE-gIzIgG complex eluted from the
column (Fig. 2, A and B). SDS-PAGE analysis of the eluted
material revealed that both gE-gI and IgG were present in the
peak (data not shown), indicating that gE-gI and IgG form a
stable complex under these conditions. When the input ratio of
gE-gI to IgG was greater than 1:1, a peak corresponding to
excess gE-gI was observed in addition to the gE-gIzIgG complex
FIG. 2. Stoichiometry determination of the gE-gIzIgG complex
using conventional gel filtration. gE-gI and IgG were incubated for
30 min at pH 7.4 at the indicated molar ratios and then passed over a
size exclusion column to separate the gE-gIzIgG complex from uncom-
plexed proteins. At a 1:1 molar ratio of gE-gI to IgG, all of the protein
chromatographs as a single complex. When the input ratio of gE-gI to
IgG is greater than 1:1, there is excess gE-gI (A), whereas when the
input ratio of IgG to gE-gI is greater than 1:1, there is excess IgG (B)
(verified by SDS-PAGE analysis; data not shown). C, gE-gI and IgG
each elute as a single peak and can be distinguished from one another
on the basis of their retention times.
FIG. 3. Sedimentation equilibrium analysis of gE-gI. gE-gI at
0.6 mg/ml was centrifuged at 10,000 rpm until equilibrium was reached
(36 h). The gradient formed can be best fit to a single species with a
mass of 83.4 kDa. The errors of the fit, shown in the residuals plot, are
small and random.
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peak, whereas a peak corresponding to excess IgG was ob-
served in addition to the complex peak when the input ratio
was less than 1:1 (Fig. 2, A and B).
To verify the 1:1 stoichiometry of the gE-gIzhIgG complex, we
also used an equilibrium-based method. In this method, a gel
filtration column was equilibrated with buffer containing a
uniform concentration of hIgG (equilibration buffer). gE-gI and
hIgG mixtures in equilibration buffer were injected over the gel
filtration column. Four injections were made, containing gE-gI
at a concentration equal to that of hIgG in the equilibration
buffer and either no additional hIgG or 1, 2, or 3 mol eq of hIgG.
In all cases, all of the injected gE-gI binds to hIgG, migrating as
the gE-gIzIgG complex. When the amount of additional hIgG
injected is less than or greater than the amount required for
formation of the gE-gIzIgG complex, a trough (in the case of too
little hIgG) or a peak (in the case of excess hIgG) should be
observed at the position where free hIgG migrates. When the
amount of additional hIgG injected is equal to that required for
formation of the gE-gIzIgG complex, a flat base line should be
observed at the position where hIgG migrates. Over the con-
centration range from 250 nM (Fig. 4A) to 5 mM (Fig. 4B),
injections of additional hIgG in an amount equivalent to that of
gE-gI in the sample result in a flat base line at the hIgG
migration position. These results verify that the stoichiometry
of the gE-gIzhIgG complex is 1:1 over a protein concentration
range of 250 nM to 5 mM.
Residue 435 at the CH2-CH3 Domain Interface Is Critical for
gE-gIzIgG Binding—Previous IgG binding studies with HSV-1-
infected cells indicated that hIgG1, hIgG2, and hIgG4 bind to
the HSV-1 FcR, while many hIgG3 allotypes do not bind (39–
41). This subtype binding preference resembles the binding
preferences for IgG binding by Staphylococcus aureus protein A
(protein A) and certain classes of rheumatoid factors (RF; an-
tibodies that bind to the Fc portion of Ig) (38, 42–45). We used
biosensor-based assays to quantitate the affinity between gE-gI
and hIgG subtypes and to characterize the molecular basis of
the observed binding specificities. Purified soluble gE-gI was
immobilized on the surface of a Biacore biosensor chip using an
amine-based coupling chemistry, as described in the Biacore
Methods manual. We analyzed the binding of chimeric murine-
hIgG molecules composed of the variable domains of a murine
anti-dansyl immunoglobulin fused to the constant domains of
hIgG1, hIgG2, hIgG3, or hIgG4 (37, 38). The chimeric hIgG
subtypes were analyzed for binding to immobilized gE-gI at low
coupling densities of gE-gI (100–300 response units), condi-
tions under which mass transport-limited binding is not signif-
icant (46). The derived binding constants are summarized in
Table I. Chimeric hIgG1, hIgG2, and hIgG4 bind to immobi-
lized gE-gI with equilibrium dissociation constant (KD) values
of 200–400 nM. Of the different hIgG subtypes, hIgG4 has the
highest affinity for gE-gI, while hIgG3 does not show detectable
binding (.5 response units) at concentrations up to 3.0 mM
(Table I and Fig. 5, A and B).
For an independent verification of the biosensor-derived af-
finities, full-length gE and gI were expressed in CHO cells (Fig.
6), and the binding affinity for hIgG4 was derived using iodi-
nated hIgG4. Scatchard analysis of the binding data yields a
KD value of 40.4 6 13 nM, compared with 199 6 35 nM in the
biosensor-based analysis (Fig. 7). The 5-fold lower affinity de-
termined using the biosensor assay could reflect that covalent
immobilization of gE-gI results in reduced affinity for IgG or
that the membrane-bound form of gE-gI has a higher affinity
for IgG than the soluble version. Although biosensor assays
may underestimate the true binding affinity of gE-gI for IgG,
they allow quantitative comparison of the relative binding af-
finities of different hIgG mutants for gE-gI.
Position 435 of hIgG sequences contains a polymorphism
that distinguishes many hIgG3 allotypes from hIgG1, hIgG2,
and hIgG4. In many hIgG3, residue 435 is an arginine; a
histidine is found in all other subclasses. Histidine 435 is a
contact residue for protein A binding to IgG Fc (47) and is also
important for the binding of some rheumatoid factors to IgG
(38, 48, 49). The inability of some RF to recognize hIgG3 can be
reversed if the G3m(st) allotype is used. Recognition of this
TABLE I
Binding of hIgG constructs to gE-gI immobilized on a Biacore chip
Kinetic constants were derived from sensorgram data using simulta-
neous fitting to the association and dissociation curves and global
fitting to all curves in a working set. Kinetic analysis was performed
using the BIAevaluation version 3.0 package. The equilibrium con-
stants, KD, were determined from the ratios of the kinetic constants.
For hIgG3, hIgG4H435R, and 3–4-3–3, signals of less than 4 RU were
observed at protein concentrations of 3.0 mM.
ka 3 10
24 kd 3 10
3 KD
Ms21 s21 nM
hIgG1 1.87 6 0.51 5.09 6 0.77 282 6 36
hIgG2 1.96 6 0.51 6.03 6 0.08 327 6 80
hIgG3
hIgG4 1.75 6 0.21 3.64 6 0.44 199 6 35
hIgG3R435H 1.55 6 0.44 12.31 6 4.09 947 6 533
hIgG4H435R
3–4-3–3
3–3-4–4 2.02 6 0.35 4.66 6 0.36 240 6 60
4–3-4–4 1.62 6 43 2.94 6 2.04 231 6 188
FIG. 4. Stoichiometry determination of the gE-gIzIgG complex using equilibrium gel filtration. A Superdex 200 column was equili-
brated with 20 mM Tris, 150 mM NaCl, pH 7.4 containing either 250 nM hIgG (A) or 5 mM hIgG (B). A, 250 nM gE-gI was injected in equilibration
buffer (20 mM Tris, 150 mM NaCl, pH 7.4, 250 nM hIgG) along with the indicated additional concentrations of hIgG. B, 5 mM gE-gI was injected in
equilibration buffer (20 mM Tris, 150 mM NaCl, pH 7.4, 5 mM hIgG) along with the indicated additional concentrations of hIgG.
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hIgG3 correlates with the presence of histidine at position 435,
while nonbinding hIgG3 have an arginine at position 435 (38,
48). Histidine 435 is located at the interface between the CH2
and the CH3 domains of IgG (Fig. 8). The CH2-CH3 domain
interface of IgG has previously been implicated as the binding
site for HSV-1 FcR, based upon inhibition studies with a pro-
teolytic fragment of protein A (50). Alteration of residue 435
could therefore account for the observed differences in gE-gI
binding to the hIgG isotypes. Alternatively, since hIgG3 has an
extended hinge compared with other hIgG isotypes, hinge-
proximal structural differences might account for the observed
subtype-specific binding preferences. To investigate these pos-
sibilities, we used biosensor assays to examine the binding of
gE-gI to mutant hIgG3 and hIgG4 proteins and switch variants
in which the constant domains of different subclasses were
exchanged by exon shuffling (37, 38).
To investigate the effect of residue 435 upon gE-gIzIgG affin-
ity, the binding of gE-gI to hIgG3 and hIgG4 mutants was
examined. The hIgG3 mutant, hIgG3R435H, contains a histi-
dine at residue 435 in place of an arginine in the wild type
protein, while the hIgG4 mutant, hIgG4H435R, contains an
arginine at residue 435 in place of the histidine in the wild type
protein (38). The single residue change of arginine to histidine
at residue 435 of hIgG3 is sufficient to restore binding from
undetectable in the case of the wild type protein to an affinity
of 947 6 533 nM in the case of the single site mutant (Fig. 5, A
and C, and Table I). The reciprocal change in hIgG4, histidine
to arginine at position 435 (hIgG4H435R), results in no binding
at concentrations up to 3 mM, as compared with a binding
affinity of 199 6 35 nM for wild type hIgG4 (Fig. 5, B and D, and
Table I).
To probe for differences in affinity due to hinge-proximal
structural effects, the binding of gE-gI to switch variants of IgG
was examined. As described previously, switch variants have
been generated by exchanging the constant domains of differ-
ent subclasses by exon shuffling (38). The switch variants used
in these studies were 3-3-4-4 (CH1 and hinge domains of hIgG3,
CH2, and CH3 domains of hIgG4), 4-3-4-4 (CH1, CH2, and CH3
domains of hIgG4, hinge of hIgG3), and 3-4-3-3 (CH1, CH2, and
the CH3 domains of hIgG3, hinge of hIgG4). Biosensor assays
indicate that the switch variants 3-3-4-4 and 4-3-4-4 bind gE-gI
with an affinity comparable with that of wild type hIgG4 (Table
I). By contrast, the switch variant 3-4-3-3 does not bind at
concentrations up to 3.0 mM (Table I). These results demon-
strate that histidine 435 at the CH2-CH3 domain interface of
IgG is critical for gE-gI binding and that the presence of the
extended hinge in the chimeric hIgG3 does not significantly
hinder binding.
DISCUSSION
We have initiated a molecular characterization of IgG bind-
ing by the herpesvirus gE-gI protein. gE and gI are known to
associate in HSV-1-infected cells and upon co-expression in
heterologous systems (8, 9). Here we show that gE and gI
assemble into a stable complex when expressed as soluble
proteins. We also show that the soluble gE-gI complex can be
purified to homogeneity based upon its Fc receptor function,
using IgG affinity chromatography. Gel filtration and analyti-
FIG. 5. Biosensor analysis of the binding of hIgG3, hIgG4, and the corresponding residue 435 mutants. Soluble gE-gI was immobilized
on the surface of a Biacore chip using a primary amine-based coupling protocol. The injected samples were 188 nM to 1.5 mM hIgG3 (A), 46–366
nM hIgG4 (B), 70.8–566 nM hIgG3R435H (C), or 250 nM to 2 mM hIgG4H435R (D). For each set of binding experiments, sensorgrams are overlaid
with the calculated response using a 1:1 binding model. One representative set of injections from experiments performed in duplicate or triplicate
is shown for each interaction.
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cal ultracentrifugation experiments establish that soluble
gE-gI is a 1:1 heterodimer, consistent with observations for
gE-gI complexes derived from other a-herpesviruses (e.g. vari-
cella zoster virus (51)). These results demonstrate that the
transmembrane and cytoplasmic domains of gE and gI are not
required for gE-gI heterodimer assembly and that the extra-
cellular domains are sufficient for the assembly of gE and gI
into a stable heterodimer.
Whereas neither gE nor gI alone efficiently bind monomeric
hIgG, the gE-gI heterodimer binds hIgG with relatively high
affinity. Biosensor-based studies using immobilized gE-gI show
that soluble gE-gI binds to hIgG1, hIgG2, and hIgG4 with
affinities in the range of 200–400 nM. Results from binding
assays using CHO cells expressing membrane-bound gE-gI are
in close agreement with the binding constant of 50 nM reported
FIG. 6. Expression of full-length gE and gI in CHO cells. CHO cells transfected with genes encoding gE and gI were assayed for surface
expression of both proteins using flow cytometry. Untransfected (dotted lines) or transfected (solid lines) cells were stained with FITC-labeled
human IgG (A), the mouse anti-gE antibody 1108 followed by FITC-labeled goat anti-mouse antibody (B), or the mouse anti-gI antibody fd69
followed by FITC-labeled goat anti-mouse antibody (C). In B and C, the dashed lines represent staining of transfected cells with FITC-labeled goat
anti-mouse antibody alone.
FIG. 7. Cell binding assay for determination of the binding
affinity of membrane-bound gE-gI for IgG. 1 3 106 CHO cells
expressing membrane-bound gE-gI were incubated with different con-
centrations of 125I-labeled chimeric hIgG4. Binding data are presented
as a Scatchard plot. Each point represents the average of two duplicate
measurements. Three independent experiments yielded an average
binding constant of 40 6 13 nM.
FIG. 8. The location of histidine 435 on the structure of human
Fc. A ribbon diagram of the CH2 and CH3 domains of hIgG are shown
(47). The side chain of histidine 435 is shown on the carbon-a back-
bone. The figure was prepared using Molscript (75) and rendered using
Raster 3D (76).
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for the interaction of rabbit IgG with HSV-1-infected cells (52).
In addition, the observed binding specificities for the gE-gI
interaction with different hIgG subclasses and rodent IgG par-
allels the binding specificities reported for IgG interaction with
HSV-1-infected cells (39, 53). Thus, our results confirm that the
FcR activity induced by HSV-1 infection of cells corresponds to
IgG binding by cell surface gE-gI heterodimers. The relatively
high affinity interaction between gE-gI and the hIgG subtypes
1, 2, and 4 indicates that nonimmune monomeric hIgG can coat
HSV-1 virions at the high concentrations of hIgG present in
serum (60–70 mM), thereby inhibiting virus neutralization by
antiviral antibodies.
Antibody bipolar bridging by gE-gI on HSV-1-infected cells
has been implicated in inhibition of ADCC mediated by mam-
malian FcgRs (20). Human peripheral blood mononuclear cells
have been shown to mediate lower levels of ADCC activity
against target cells infected with wild type HSV-1 compared
with cells infected with a gE-negative HSV-1. These differences
were attributed to the engagement of the Fc regions of cell
surface-associated antibodies by cognate gE-gI rather than by
the FcgR present on opposing immune effector cells. Among
mammalian receptors, FcgRI (KD ;0.5 3 10
29 M) is a high
affinity receptor, and FcgRII and FcgRIII (KD ,1 3 10
26 M) are
low affinity receptors (reviewed in Refs. 54 and 55). Thus,
based upon affinity considerations alone, the formation of a
gE-gIzIgG complex is likely to inhibit ADCC mediated by
FcgRII and FcgRIII. In addition, the observed 1:1 stoichiome-
try for IgG interaction with gE-gI, FcgRI, and FcgRIII, as well
as the fact that only one of two available binding sites on IgG is
a high affinity site in the FcRn-IgG complex (reviewed in Refs.
54 and 55), suggests a marked asymmetry in the Fc regions of
receptor-bound IgGs, such that only one of the binding sites is
in an optimal conformation for binding to many receptors. The
observed 1:1 stoichiometry of the gE-gIzIgG complex at micro-
molar concentrations of the proteins indicates that the asym-
metry of the gE-gIzIgG complex may prevent high affinity in-
teraction with a second gE-gI molecule. Similar mechanisms
could also account for a reduced reactivity of the gE-gIzIgG
complex with other Fcg binding proteins, irrespective of the
binding site location.
The 1:1 stoichiometry of the gE-gIzIgG complex could have
implications for signaling mediated by IgG binding to cell sur-
face gE-gI. Specifically, binding of monomeric IgG would not be
expected to induce dimerization of gE-gI heterodimers. How-
ever, aggregated IgG (such as IgG in immune complexes) or
anti-gE and anti-gI antibodies could result in gE-gI multimer-
ization. In addition, IgG involved in antibody bipolar bridging
(21) could result in the oligomerization of gE-gI with other viral
glycoproteins. A conserved YXX(L/V) motif is observed in the
cytoplasmic domains of gE from HSV-1, HSV-2, and PRV (33,
56, 57). In mammalian receptors, the YXX(V/L) motif is respon-
sible for various signaling events such as the internalization of
endocytic receptors from the plasma membrane, protein target-
ing to various cellular compartments (58), mediation of im-
mune cell activation (59), and inhibition of cellular immune
responses (60). The importance of the YXXL motif in mamma-
lian immune responses raises the question of whether the
gE-encoded YXXL motif is functional in signal transduction
mediated by Fc binding. The FcR activity of gE-gI has been
suggested to initiate signaling events that facilitate capping
and extrusion of PRV glycoproteins, induced by a polyclonal
mixture of porcine anti-PRV antibodies (13). Whether anti-
HSV antibodies can mediate glycoprotein capping and extru-
sion in HSV-infected cells remains an important question to be
addressed. If antibody-induced capping and extrusion of viral
glycoproteins occurs in HSV-1-infected cells, the importance of
Fc binding by gE-gI for the occurrence of the process can be
rigorously investigated with the current knowledge of gE-gI
binding specificities for different IgG and the interaction stoi-
chiometry. These studies will allow a better understanding of
the mechanisms by which the FcR activity of a-herpesviruses
could modify the protective effects of antiviral antibodies.
Antibody bipolar bridging has been implicated in inhibition
of ADCC by HSV (20) as well as in anti-PRV antibody-mediated
glycoprotein capping and extrusion (13); but is antibody bipolar
bridging sterically probable? Can an IgG molecule simulta-
neously use its Fab and the Fc regions in interactions with
antigens and Fc receptors? Although direct evidence for the
occurrence of antibody bipolar bridging is lacking, fluorescence
energy transfer studies indicate that the IgG molecule is highly
flexible (61), suggesting that simultaneous interactions of the
Fab and Fc domains as postulated in antibody bipolar bridging
are feasible.
Using mutant forms of hIgG, we show that histidine 435 at
the interface between the CH2 and CH3 domains of IgG is
critical for the binding interaction. Other proteins known to
interact at the CH2-CH3 domain interface include protein A
(47), protein G (62), the neonatal Fc receptor (63), and RF (44).
Crystal structures have been reported for Fc complexes with
protein A (47), protein G (64), neonatal Fc receptor (65), and a
Fab fragment derived from a human IgM RF antibody (RF-AN)
(49, 66). From comparisons of the binding characteristics ob-
served for the gE-gIzIgG complex and IgG complexes with pro-
tein A, protein G, neonatal Fc receptor, and RF, it appears that
the gE-gIzIgG complex most closely resembles IgG complexes
with certain rheumatoid factors. The similarities include a lack
of binding of several hIgG3 allotypes, the species specificity
(binding to human and rabbit IgG, but lack of binding of rodent
IgG (39, 53, 66)), and the importance of histidine 435 in the
binding interaction. That the IgG binding specificity of gE-gI
closely resembles that of some RF is significant in understand-
ing the origin of RF, since it has been suggested that some RF
arise as anti-idiotypic antibodies against antibodies to bacterial
or viral Fcg-binding proteins, in a process known as idiotypic
networking (44, 67, 68).
Anti-idiotypic antibodies recognize the idiotypic determi-
nants expressed in the V region of a particular antibody or the
V regions of a group of related antibodies. It has been proposed
that anti-idiotypic antibodies are expressed in order to regulate
the expression of antibodies that dominate the response to a
particular antigen (69). Suppression of B cells expressing these
dominant antibodies would allow for the proliferation of other
antibodies using alternative V region sequences and ultimately
to the diversification of the antibody response (70). While the
expression of anti-idiotypic antibodies would normally decline
with the decreased expression of the antibodies to which they
are responding, anti-idiotypic antibodies that cross-react with
something so ubiquitous as self-IgG have the potential to be
continually propagated. This model of idiotypic suppression
provides a possible explanation for the production of RF as a
result of HSV-1 infection. Expression of gE-gI on the virion and
on the surface of HSV-1-infected cells would lead to production
of anti-gE-gI antibodies and subsequently to the production of
anti-anti-gE-gI antibodies that have the potential to be RF if
the epitope recognized by the anti-gE-gI antibody is the region
on gE-gI that interacts with IgG-Fc. In addition, persistence of
HSV-I infection may lead to continual production of RF.
The similarities we observe between the gE-gIzIgG complex
and IgG complexes with certain classes of RF support the
hypothesis that some RF might be anti-idiotypic antibodies
against antibodies to gE-gI and provide the basis to more
closely examine the linkage between herpesviral infections and
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pathogenic RF production. Further support comes from studies
by Tsuchiya et al. (71), which show that some RF share idio-
typic determinants with gE-gI, suggesting that these RF may
be anti-idiotypic antibodies against antibodies to gE-gI. How-
ever, whether the observed similarities in binding characteris-
tics of gE-gIzIgG and the RF-IgG complexes will correspond to
similarities in the interactions at the atomic level remains to be
determined from crystallographic comparisons of gE-gIzIgG
with RFzIgG complexes that show the closest resemblance in
binding characteristics.
Recent studies suggest that antibodies are highly protective
against herpes infections in human neonates (72). Based upon
the binding studies reported here and previous studies with
HSV-1-infected cells (39, 40, 53), gE-gI can mitigate the effects
of antiviral antibodies of the IgG1, IgG2, and IgG4 subtypes,
whereas IgG3 allotypes might confer the greatest protection to
a host due to the inability of many IgG3 allotypes to bind gE-gI.
HSV-specific antibodies of the IgG1, IgG3, and IgG4 subclasses
have been detected in genital herpes infections (73). Because
human neonatal Fc receptor (the receptor responsible for trans-
placental IgG transfer (74)) binds the four human IgG isotypes
with similar affinities,2 IgG3 is likely to be transferred to the
fetus with equal efficacy compared with the other isotypes that
are generated, and it may constitute the isotype that confers
the greatest protection against neonatal herpes. However, it is
possible that anti-HSV hIgG3 antibodies are not produced or
are not effective in certain HSV infections, and therefore, a
virus expressing an IgG3-binding FcR would not experience a
selective advantage. This may explain the lack of hIgG3 bind-
ing to gE-gI and the evolution of the viral FcR with specificity
for other hIgG subclasses.
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